Endometrioid adenocarcinoma
MONDO:0005026An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.
Also known as: endometrioid adenocarcinoma, endometrioid carcinoma, endometrioid carcinoma of female reproductive system, endometrioid carcinoma of the female reproductive system, female reproductive endometrioid carcinoma
2975 clinical trials for this condition and its sub-types, 12 tagged with Endometrioid adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Endometrioid adenocarcinoma
-
Ovarian endometrioid adenocarcinoma 77 trials
1 sub-type
-
Endometrial endometrioid adenocarcinoma 55 trials
5 sub-types
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells 0 trials
- Mucin-rich endometrial endometrioid adenocarcinoma 0 trials
- Oxyphilic endometrial endometrioid adenocarcinoma 0 trials
- Secretory uterine corpus endometrioid adenocarcinoma 0 trials
- Villoglandular endometrial endometrioid adenocarcinoma 0 trials
-
Stage I endometrioid carcinoma 16 trials
-
Stage II endometrioid carcinoma 2 trials
-
Cervical endometrioid adenocarcinoma 0 trials
1 sub-type
-
Immunotherapy duo shows promise for Tough-to-Treat uterine cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, works better than nivolumab alone for women with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). About 81 participants will receive either the combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Hormone-Blocking drug shows promise in cancer trial
Disease control Recruiting nowThis study tests MK-5684, a drug that blocks the body from making steroid hormones, in people with breast, ovarian, or endometrial cancer. Researchers want to see if it helps patients live longer without their cancer growing compared to standard treatments. The trial is recruitin…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can hormone therapy spare fertility in a challenging endometrial cancer?
Disease control Recruiting nowThis trial is testing two hormone-based approaches to treat early-stage, grade 2 endometrial cancer in women under 45 who wish to preserve their fertility. One approach uses a daily oral progesterone pill, while the other combines the pill with a hormone-releasing intrauterine de…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can immunotherapy plus hormones spare the womb in early endometrial cancer?
Disease control Recruiting nowThis trial is investigating whether combining an immunotherapy drug (a PD-1 inhibitor like sintilimab or pembrolizumab) with progesterone therapy can help young women with early-stage, mismatch repair-deficient (MMRd) endometrial cancer achieve complete remission while preserving…
Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New collagen shot may help young women beat uterine cancer without hysterectomy
Disease control Recruiting nowThis study tests whether injecting a lab-made collagen into the uterus, along with daily hormone pills, can help shrink early-stage endometrial cancer or precancerous growths. The goal is to preserve fertility in women aged 45 or younger. Thirty participants will either receive t…
Phase 2 • Sponsor: Wang Jianliu • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug combo shows promise for Hard-to-Treat gynecological cancers
Disease control Recruiting nowThis study tests whether a combination of two drugs, VS-6766 and defactinib, can shrink or control certain gynecological cancers that have come back. It includes women with endometrioid, ovarian, or cervical cancers that have specific gene changes (RAS, BRAF, or NF1). The goal is…
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New vaccine aims to outsmart ovarian cancer recurrence
Disease control Recruiting nowThis phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to targe…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Large study aims to pinpoint cancer return rates and swelling risks after treatment
Knowledge-focused Recruiting nowThis study is observing about 1,715 people with early-stage endometrial cancer to see how often the cancer comes back and how often lymphedema (swelling) happens after standard treatment. Participants will have regular check-ups for 36 months. The goal is to gather real-world dat…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC